Nav: Home

Gene mutation and use of certain antidepressants may decrease effects of breast cancer drug

June 05, 2004

Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug. The findings, to be reported at the 40th annual meeting of the American Society of Clinical Oncology on June 5, may tell physicians which women might have reduced benefit from tamoxifen therapy. Results also suggest that some frequently prescribed antidepressants may reduce tamoxifen's effects because the antidepressants affect a similar metabolic pathway.

Although a test for the mutation in the CYP2D6 gene is not widely available, the investigators recommend that women currently on long-term tamoxifen therapy and using such antidepressants as paroxetine and sertraline consult their health care provider for guidance. These drugs, known as selective serotonin reuptake inhibitors (SSRIs) include such well-known brands as Paxil and Zoloft. The investigators estimate the prevalence of the CYP2D6 mutation to be approximately 40 percent, and in this study of 80 women, 35 percent had the mutation.

"There's no evidence from this study that a woman who is taking tamoxifen should automatically stop using a particular antidepressant if it is helping her," says Vered Stearns, M.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. But the researchers advise that women on tamoxifen who are considering antidepressant therapy, may opt to use an antidepressant, such as venlafaxine, which may not alter tamoxifen's metabolism and has less of an effect on tamoxifen.

"Our findings are leading us in the direction of recommending therapies based on an individual's genetic profile," says Stearns. "If a woman has a particular gene mutation, we may be able to predict how she'll react to a therapy."

Tamoxifen is widely prescribed to reduce the risk of breast cancer recurrence or spread and increasingly is given in efforts to prevent breast cancer in women at high risk for the disease.

The CYP2D6 gene controls production of an enzyme that breaks down and processes tamoxifen. Mutations in the gene reduce the enzyme's ability to properly break down tamoxifen.

The women in the study had taken tamoxifen daily for four months. Analysis of blood levels of a newly characterized byproduct, called endoxifen, were approximately 75 percent lower in women with a CYP2D6 mutation in both copies of the gene. The lower levels of endoxifen suggest that mutation alters the metabolism of tamoxifen and may affect potency of the drug.

"At this point, we do not know precisely what lower levels of endoxifen signify, or if other byproducts of tamoxifen metabolism are equally or more important to measure for monitoring tamoxifen's effectiveness," cautions Stearns.

The investigators also found lower endoxifen levels in women taking antidepressant drugs regardless of whether or not they had a CYP2D6 gene mutation. Certain antidepressant drugs, such as paroxetine and sertraline, are known to block the CYP2D6 enzyme. Antidepressants are being prescribed in up to 20 percent of breast cancer patients for depression, anxiety, other psychiatric disorders or hot flashes, a common side effect of tamoxifen.

In upcoming studies, the investigators will compare antidepressant therapies in women taking tamoxifen and how gene variations in the estrogen receptors of breast cancer patients may impact the effectiveness of tamoxifen.
-end-
This research was funded by the National Institutes of Health (NIH/NIGMS).

Additional participants in this research were Yan Jin, Bryan Ward, Todd Skaar, Anna Maria Storniolo, Anne Nguyen, Zeruesenay Desta and David A. Flockhard from Indiana University School of Medicine; and Linda Ullmer, Jill Hayden and Daniel F. Hayes from the University of Michigan.

Abstract #508, Proceeding of the American Society of Clinical Oncology, 2004.

Links:
ASCO: http://www.asco.org
Johns Hopkins Kimmel Cancer Center: http://www.hopkinskimmelcancercenter.org

Johns Hopkins Medicine

Related Antidepressants Articles:

Antidepressants during pregnancy associated with childhood language disorders
Mothers who purchased antidepressants at least twice during pregnancy had a 37 percent increased risk of speech and/or language disorders among their offspring compared to mothers with depression and other psychiatric disorders who were not treated with antidepressants, according to new research by scientists at Columbia University's Mailman School of Public Health, Columbia University Medical Center and the New York State Psychiatric Institute.
Why do antidepressants take so long to work?
An episode of major depression can be crippling, impairing the ability to sleep, work, or eat.
Antidepressants commonly and increasingly prescribed for nondepressive indications
In a study appearing in the May 24/31 issue of JAMA, Jenna Wong, M.Sc., of McGill University, Montreal, Canada, and colleagues analyzed treatment indications for antidepressants and assessed trends in antidepressant prescribing for depression.
Nutrient supplements can give antidepressants a boost
An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.
Heart attack patients more depressed but get less antidepressants
Heart attack patients are more depressed but are less often prescribed antidepressants than people who have not had a heart attack, according to research presented today at EuroHeartCare 2016 by Dr.
SSRI antidepressants not associated with an increased risk of cardiovascular conditions
Commonly used antidepressants, known as selective serotonin reuptake inhibitors, are not associated with an increased risk of cardiovascular conditions, such as heart attacks and strokes in people aged below 65, finds a study published in The BMJ today.
SSRI antidepressants not associated with an increased risk cardiovascular conditions
Commonly used antidepressants, known as 'selective serotonin reuptake inhibitors', are not associated with an increased risk of cardiovascular conditions, such as heart attacks and strokes, according to new research at The University of Nottingham.
Investigating potential fetal exposure to antidepressants
Depression is a serious issue for expecting mothers. Left untreated, depression could have implications for a fetus's health.
Antidepressants during pregnancy do not pose risk to unborn child
Women who take antidepressants during pregnancy do not appear to be at greater risk of giving birth to children with congenital heart defects compared to women who are not exposed to the drugs, according to new research from UCL.
Antidepressants double the risk of aggression and suicide in children
Children and adolescents have a doubled risk of aggression and suicide when taking one of the five most commonly prescribed antidepressants, according to findings of a study published in The BMJ today.

Related Antidepressants Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...